文献速递血栓与止血

儿童内脏静脉血栓形成的抗凝治疗:系统综述与Meta分析

Anticoagulant treatment for pediatric splanchnic vein thrombosis: a systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2023-05-22

该系统综述与Meta分析纳入17项观察性研究共506例0-18岁儿童内脏静脉血栓形成患者,评估抗凝治疗的有效性与安全性。抗凝患者血管再通合并比例为55.3%(95%CI 34.1%-74.7%;I²=74.0%),非抗凝患者为29.4%(95%CI 2.6%-86.6%;I²=49.0%)。作者认为抗凝似乎与中等再通率和低大出血风险相关。

要点

  • 抗凝患者血管再通合并比例55.3%,非抗凝患者29.4%,异质性分别为I²=74.0%和I²=49.0%。
  • 抗凝患者大出血率3.8%,非抗凝患者1.4%;抗凝患者VTE复发率3.5%,非抗凝患者0%。
  • 抗凝患者死亡率10.0%,非抗凝患者50.3%;作者认为抗凝似乎与中等再通率和低大出血风险相关。

核心结论

  • 在儿童内脏静脉血栓形成中,抗凝似乎与中等再通率和低大出血风险相关,VTE复发率低且与儿童其他类型诱发性VTE相当。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和EMBASE数据库至2021年12月,纳入报告抗凝治疗及结局的观察性研究和干预性研究。
  • 共纳入17项观察性研究、506例0-18岁儿童内脏静脉血栓形成患者。

主要发现

  • 多数患者为门静脉血栓(n=308,60.8%)或Budd-Chiari综合征(n=175,34.6%),多数事件由短暂诱发因素触发。
  • 217例(42.9%)患者接受抗凝治疗(肝素类和维生素K拮抗剂),148例(29.2%)患者接受血管干预。
  • 抗凝患者血管再通合并比例为55.3%(95%CI 34.1%-74.7%;I²=74.0%),非抗凝患者为29.4%(95%CI 2.6%-86.6%;I²=49.0%)。
  • 抗凝患者SVT扩展、大出血、VTE复发和死亡率分别为8.9%、3.8%、3.5%和10.0%,非抗凝患者分别为2.8%、1.4%、0%和50.3%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical characteristics of splanchnic vein thrombosis (SVT) in pediatric patients and its optimal treatment strategies are unknown. OBJECTIVES: This study aimed to assess the effectiveness and safety of anticoagulant therapy for pediatric SVT. METHODS: MEDLINE and EMBASE databases were searched up to December 2021. We included observational and interventional studies that enrolled pediatric patients with SVT and reported anticoagulant treatment and outcomes, including rates of vessel recanalization, SVT extension, venous thromboembolism (VTE) recurrence, major bleeding, and mortality. Pooled proportions of vessel recanalization were calculated with their 95% CI. RESULTS: A total of 506 pediatric patients (aged 0-18 years) across 17 observational studies were included. The majority of patients had portal vein thrombosis (n = 308, 60.8%) or Budd-Chiari syndrome (n = 175, 34.6%). Most events were triggered by transient provoking factors. Anticoagulation (heparins and vitamin K antagonists) was prescribed in 217 (42.9%) patients, and 148 (29.2%) patients underwent vascular interventions. The overall pooled proportions of vessel recanalization were 55.3% (95% CI, 34.1%-74.7%; I2 = 74.0%) among anticoagulated patients and 29.4% (95% CI, 2.6%-86.6%; I2 = 49.0%) among non-anticoagulated patients. SVT extension, major bleeding, VTE recurrence, and mortality rates were 8.9%, 3.8%, 3.5%, and 10.0%, respectively, in anticoagulated patients and 2.8%, 1.4%, 0%, and 50.3%, respectively, in non-anticoagulated patients. CONCLUSION: In pediatric SVT, anticoagulation appears to be associated with moderate recanalization rates and a low risk of major bleeding. VTE recurrence is low and comparable to that reported in pediatric patients with other types of provoked VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cohen O, Efros O, Riva N, et al. Anticoagulant treatment for pediatric splanchnic vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2023. PMID: 37225019. doi:10.1016/j.jtha.2023.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。